Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$15.65
-0.18-1.14%
al cierre: -
$15.68
0.030.19%
After hour: 6:12 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Arcutis Biotherapeutics Inc ha un obiettivo di prezzo di consenso pari a $24.73, stabilito in base alle ultime valutazioni degli analisti di 13. Le ultime 3 valutazioni degli analisti sono state rilasciate da Needham, Goldman Sachs y Needham il agosto 7, 2025, julio 25, 2025 y mayo 23, 2025. Con un obiettivo di prezzo medio di $20 tra le Needham, Goldman Sachs y Needham, c'è un implicito 27.55% upside per Arcutis Biotherapeutics Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Needham
Goldman Sachs
HC Wainwright & Co.
Jefferies
Goldman Sachs
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Arcutis Biotherapeutics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/07/2025 | 40.31% | Needham | $20 → $22 | Maintains | Buy | |||
07/25/2025 | 14.8% | Goldman Sachs | → $18 | Initiates | → Neutral | |||
05/23/2025 | 27.55% | Needham | $20 → $20 | Reiterates | Buy → Buy | |||
04/09/2025 | 27.55% | Needham | $20 → $20 | Reiterates | Buy → Buy | |||
04/03/2025 | — | Guggenheim | — | Reiterates | Buy → Buy | |||
04/03/2025 | 21.17% | HC Wainwright & Co. | $19 → $19 | Reiterates | Buy → Buy | |||
04/03/2025 | 27.55% | Needham | $20 → $20 | Reiterates | Buy → Buy | |||
03/11/2025 | 21.17% | Jefferies | $16 → $19 | Maintains | Buy | |||
02/27/2025 | -4.34% | Goldman Sachs | $13 → $15 | Maintains | Neutral | |||
02/26/2025 | 21.17% | HC Wainwright & Co. | $19 → $19 | Reiterates | Buy → Buy | |||
02/26/2025 | 33.93% | Mizuho | $20 → $21 | Maintains | Outperform | |||
02/26/2025 | 27.55% | Needham | $20 → $20 | Reiterates | Buy → Buy | |||
02/24/2025 | — | Guggenheim | — | Reiterates | Buy → Buy | |||
02/10/2025 | — | Guggenheim | — | Reiterates | Buy → Buy | |||
01/13/2025 | 21.17% | HC Wainwright & Co. | $19 → $19 | Reiterates | Buy → Buy | |||
01/07/2025 | 27.55% | Mizuho | $19 → $20 | Maintains | Outperform | |||
12/30/2024 | 21.17% | HC Wainwright & Co. | → $19 | Initiates | → Buy | |||
12/17/2024 | 27.55% | Needham | $18 → $20 | Maintains | Buy | |||
11/07/2024 | 14.8% | Needham | $18 → $18 | Reiterates | Buy → Buy | |||
08/28/2024 | -4.34% | Jefferies | → $15 | Initiates | → Buy | |||
08/15/2024 | 14.8% | Needham | $18 → $18 | Reiterates | Buy → Buy | |||
07/30/2024 | 14.8% | Needham | $18 → $18 | Reiterates | Buy → Buy | |||
07/10/2024 | 14.8% | Needham | $18 → $18 | Reiterates | Buy → Buy | |||
05/15/2024 | 14.8% | Needham | $16 → $18 | Maintains | Buy | |||
05/15/2024 | 14.8% | Mizuho | $17 → $18 | Maintains | Buy | |||
04/12/2024 | 2.04% | Needham | $16 → $16 | Reiterates | Buy → Buy | |||
02/28/2024 | -29.85% | Goldman Sachs | $6 → $11 | Maintains | Neutral | |||
02/28/2024 | 8.42% | Mizuho | $16 → $17 | Reiterates | Buy → Buy | |||
02/28/2024 | 2.04% | Needham | $8 → $16 | Maintains | Buy | |||
02/23/2024 | 2.04% | Mizuho | $8 → $16 | Reiterates | Buy → Buy | |||
01/03/2024 | -48.98% | Mizuho | $4 → $8 | Upgrade | Neutral → Buy | |||
01/02/2024 | -48.98% | Mizuho | $4 → $8 | Upgrade | Neutral → Buy | |||
11/13/2023 | -36.22% | Morgan Stanley | $45 → $10 | Maintains | Overweight | |||
11/08/2023 | — | JonesTrading | — | Downgrade | Buy → Hold | |||
11/06/2023 | -48.98% | Needham | $22 → $8 | Maintains | Buy | |||
11/06/2023 | -48.98% | HC Wainwright & Co. | $22 → $8 | Maintains | Buy | |||
10/27/2023 | -74.49% | Mizuho | $57 → $4 | Downgrade | Buy → Neutral | |||
10/13/2023 | -61.73% | Goldman Sachs | $32 → $6 | Downgrade | Buy → Neutral | |||
09/25/2023 | 263.52% | Mizuho | → $57 | Reiterates | Buy → Buy | |||
08/22/2023 | 218.88% | Cantor Fitzgerald | → $50 | Reiterates | Overweight → Overweight | |||
08/10/2023 | 40.31% | Needham | → $22 | Reiterates | Buy → Buy | |||
08/09/2023 | 218.88% | TD Cowen | $65 → $50 | Maintains | Outperform | |||
07/18/2023 | 53.06% | Needham | → $24 | Reiterates | Buy → Buy | |||
06/28/2023 | 218.88% | Cantor Fitzgerald | → $50 | Reiterates | Overweight → Overweight | |||
06/12/2023 | 263.52% | Mizuho | → $57 | Reiterates | Buy → Buy | |||
05/26/2023 | 155.1% | Truist Securities | $45 → $40 | Maintains | Buy | |||
05/17/2023 | 53.06% | Needham | → $24 | Reiterates | Buy → Buy | |||
05/11/2023 | 110.46% | Goldman Sachs | $44 → $33 | Maintains | Buy | |||
05/10/2023 | 186.99% | Morgan Stanley | $47 → $45 | Maintains | Overweight | |||
05/10/2023 | 263.52% | Mizuho | $61 → $57 | Maintains | Buy | |||
04/19/2023 | 53.06% | Needham | → $24 | Reiterates | → Buy | |||
04/12/2023 | 199.75% | Morgan Stanley | $50 → $47 | Maintains | Overweight | |||
04/11/2023 | 289.03% | Mizuho | → $61 | Reiterates | → Buy | |||
03/29/2023 | 186.99% | Truist Securities | $50 → $45 | Maintains | Buy | |||
03/16/2023 | 53.06% | Needham | $46 → $24 | Maintains | Buy | |||
03/01/2023 | 218.88% | Morgan Stanley | $51 → $50 | Maintains | Overweight | |||
03/01/2023 | 193.37% | Needham | → $46 | Reiterates | → Buy | |||
12/13/2022 | 225.26% | Morgan Stanley | $49 → $51 | Maintains | Overweight | |||
10/04/2022 | 212.5% | Morgan Stanley | $46 → $49 | Maintains | Overweight | |||
09/27/2022 | 193.37% | Morgan Stanley | $45 → $46 | Maintains | Overweight | |||
09/22/2022 | 244.39% | JonesTrading | → $54 | Assumes | → Buy | |||
09/07/2022 | 193.37% | Needham | → $46 | Initiates | → Buy |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Arcutis Biotherapeutics (ARQT)?
El último precio objetivo de Arcutis Biotherapeutics (NASDAQ:ARQT) fue comunicado por Needham el agosto 7, 2025. La firma de analistas fijó un precio objetivo para $22.00 que espera ARQT a rise dentro de 12 meses (un posible 40.31% upside). 19 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Arcutis Biotherapeutics (ARQT)?
La última calificación de analistas para Arcutis Biotherapeutics (NASDAQ:ARQT) fue proporcionada por Needham, y Arcutis Biotherapeutics mantuvo su buy calificación.
¿Cuándo se produjo la última revisión al alza de Arcutis Biotherapeutics (ARQT)?
La última revisión al alza de Arcutis Biotherapeutics Inc se produjo en enero 3, 2024, cuando Mizuho elevó su precio objetivo a $8. Mizuho anteriormente tenía a neutral para Arcutis Biotherapeutics Inc.
¿Cuándo fue la última revisión a la baja de Arcutis Biotherapeutics (ARQT)?
La última revisión a la baja de Arcutis Biotherapeutics Inc se produjo en noviembre 8, 2023, cuando JonesTrading cambió su precio objetivo de N/A a N/A para Arcutis Biotherapeutics Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Arcutis Biotherapeutics (ARQT)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Arcutis Biotherapeutics, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Arcutis Biotherapeutics se registró el agosto 7, 2025, por lo que la próxima calificación estará disponible en torno al agosto 7, 2026.
¿Es correcta la calificación de los analistas sobre Arcutis Biotherapeutics (ARQT)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Arcutis Biotherapeutics (ARQT) fue un mantuvo con un precio objetivo de $20.00 a $22.00. El precio actual al que cotiza Arcutis Biotherapeutics (ARQT) es de $15.68, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.